Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine Gross Profit Margin (Quarterly) : 96.29% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.29% |
| June 30, 2026 | 96.50% |
| March 31, 2026 | 82.94% |
| December 31, 2025 | 96.75% |
| September 30, 2025 | 90.44% |
| June 30, 2025 | 48.74% |
| March 31, 2025 | 58.84% |
| December 31, 2024 | 95.49% |
| September 30, 2024 | -2.52K% |
| June 30, 2024 | -176.8% |
| March 31, 2024 | -24.14% |
| December 31, 2023 | 97.56% |
| September 30, 2023 | 71.63% |
| June 30, 2023 | 46.66% |
| March 31, 2023 | 84.33% |
| December 31, 2022 | 75.87% |
| September 30, 2022 | -3.72K% |
| June 30, 2022 | 74.88% |
| March 31, 2022 | 76.99% |
| December 31, 2021 | 87.88% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| Date | Value |
|---|---|
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Vertex Pharmaceuticals, Inc. | 84.70% |
| Recursion Pharmaceuticals, Inc. | -9.13% |
| Halozyme Therapeutics, Inc. | 77.28% |
| Novavax, Inc. | 71.03% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -153.7% |
| Return on Assets | -36.32% |
| Return on Invested Capital | -59.75% |
| Profit Margin (Quarterly) | -225.7% |
| Operating Margin (Quarterly) | -234.3% |
| Return on Net Operating Assets | -284.4% |